FDA Approves New Oral PCSK9 Inhibitor Pill for Lowering Cholesterol

1-Minute Brief

The approval introduces a new treatment option for patients who need to lower cholesterol beyond what statins achieve.

Key Facts

• The FDA has approved a new pill designed to lower cholesterol levels.
• The medication is called Lipfendra and is the first once-daily oral PCSK9 inhibitor.
• Clinical trials showed the new pills can lower cholesterol levels more than statins alone.
• When combined with statins, Lipfendra reduced LDL cholesterol by approximately 56% to 60%.
• The new pill targets patients who require greater cholesterol reduction than current therapies provide.

What Happened

The FDA approved Lipfendra, a once-daily oral PCSK9 inhibitor, after clinical trials showed it significantly lowers LDL cholesterol, especially when used with statins.

Why It Matters

This approval provides an additional option for patients at risk of cardiovascular disease who need to lower cholesterol beyond what existing treatments offer.

What's Next

Healthcare providers may begin prescribing Lipfendra to eligible patients. Further monitoring and post-market studies may assess long-term safety and effectiveness.